All In Biotech

Drug Trial Radar · NCT07102095

A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose

A Phase 1, Open-label, Single-dose Study to Assess the Influence of Hepatic Impairment on the Pharmacokinetics of of Sevabertinib (BAY 2927088)

Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Jul 24, 2025

Primary completion

Dec 3, 2025

Study completion Dec 3, 2025

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Aug 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a research study to understand how liver impairment affects the way the body processes a new cancer medicine called sevabertinib (BAY 2927088). Sevabertinib is an experimental drug being developed to treat certain types of cancers that have specific genetic changes called HER2 mutations. This includes lung cancer, tumors that have spread to other parts of the body (metastatic), and tumors that cannot be removed with surgery (unresectable). Before this medicine can be given to cancer patients with liver problems, researchers need to understand how liver disease might change the way the body handles the drug. The study will include about 20 people divided into two groups: 10 people with moderate liver problems (called Child-Pugh B liver impairment) and 10 healthy people with normal liver function. The healthy volunteers will be matched to the liver patients by age, sex, and weight to make fair comparisons. All participants will take a single 20 mg dose of sevabertinib by mouth and stay in the research clinic for 5 days. During this time, researchers will take blood samples at specific times to measure how much drug is in the blood and how long it stays in the body. They will also monitor participants closely for any side effects. The main goal is to see if people with liver problems have different drug levels in their blood compared to healthy people. This information will help doctors determine if cancer patients with liver disease need different doses of sevabertinib to be safe and effective. The study will also look at the safety and tolerability of sevabertinib in both groups. Participants will have follow-up visits to ensure their continued health and safety. This research is important because many cancer patients also have liver problems, and understanding how liver disease affects this new cancer treatment will help ensure it can be used safely and effectively in all patients who might benefit from it.

Conditions

  • Hepatic Insufficiency
  • Liver Diseases
  • Pharmacokinetics
  • Drug Metabolism

Interventions

  • SevabertinibDrug

    Single oral dose of 20 mg sevabertinib administered as 2 x 10 mg film-coated tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under plasma concentration-time curve (AUC) of sevabertinibTime frame: 0-96 hours post-dose
  2. Unbound area under plasma concentration-time curve AUC (AUCu) of sevabertinibTime frame: 0-96 hours post-dose
  3. Maximum observed drug concentration (Cmax) of sevabertinib in plasmaTime frame: 0-96 hours post-dose
  4. Unbound Cmax (Cmax,u) of sevabertinib in plasmaTime frame: 0-96 hours post-dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Pharmacology of Miami - Oncology

    Miami, Florida

  • Orlando Clinical Research Center

    Orlando, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.